Leigh Ann Bruhn, director of Avalere Health, addresses results from "DIMENSIONS of Specialty Pharmaceuticals: Evolving Trends in Market Access," a new study conducted by Avalere Health and commissioned by Janssen Biotech, Inc. and Johnson & Johnson Health Care Systems.
FDA Approves Combination Therapy for Pulmonary Arterial Hypertension
March 25th 2024J&J’s Opsynvi is single-tablet combination of macitentan, an endothelin receptor antagonist, and tadalafil, a PDE5 inhibitor. It will be priced on parity with Opsumit, which is also a J&J product to treat patients with PAH.